Liberum Biotech utilizes a cell-free protein synthesis system combined with proprietary high-yield reagents to rapidly generate actionable data for protein manufacturing. This approach significantly reduces costs and accelerates the development of enzyme candidates and antibody binding solutions compared to traditional methods.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional protein manufacturing methods are often slow and expensive, hindering the rapid development of enzyme candidates and antibody binding solutions. Existing approaches struggle to provide actionable data quickly and cost-effectively.
Solution
Liberum Biotech offers a cell-free protein synthesis system coupled with proprietary high-yield reagents to accelerate protein manufacturing and reduce costs. Their technology enables the rapid generation of real-world data, providing actionable insights for enzyme and antibody development. By leveraging a cell-free approach, Liberum Biotech delivers faster results at a lower cost compared to conventional methods. The system facilitates the efficient prototyping and optimization of protein-based solutions.
Target Audience
Liberum Biotech's primary customers are biotechnology companies and research institutions involved in enzyme engineering, antibody development, and protein manufacturing.
Features
- Proprietary high-yield cell-free reagents for efficient protein synthesis
- Cartridges for scale-up and purification utilizing thin-film technology
- Protein synthesis as a service, leveraging the cell-free system
- Library design services to improve enzyme activity and antibody binding
- AI-based protein design capabilities